 Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 2 | 5 | | 2000 | 3 | 1 | 4 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 7 | 1 | 8 | | 2004 | 5 | 6 | 11 | | 2005 | 3 | 11 | 14 | | 2006 | 3 | 6 | 9 | | 2007 | 9 | 11 | 20 | | 2008 | 11 | 8 | 19 | | 2009 | 15 | 17 | 32 | | 2010 | 17 | 8 | 25 | | 2011 | 14 | 11 | 25 | | 2012 | 21 | 5 | 26 | | 2013 | 16 | 15 | 31 | | 2014 | 24 | 12 | 36 | | 2015 | 23 | 7 | 30 | | 2016 | 19 | 11 | 30 | | 2017 | 29 | 20 | 49 | | 2018 | 36 | 20 | 56 | | 2019 | 27 | 15 | 42 | | 2020 | 22 | 38 | 60 | | 2021 | 12 | 34 | 46 | | 2022 | 7 | 47 | 54 | | 2023 | 5 | 33 | 38 | | 2024 | 40 | 35 | 75 | | 2025 | 22 | 4 | 26 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Massengill D, Abou Nader MF, Good R, Sam Wang G. Persistent Biventricular Cardiac Dysfunction Following a Large, Acute?Metformin Overdose. Pediatrics. 2025 Jun 01; 155(6).
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 Jul; 27(7):3943-3956.
-
Knowler WC, Doherty L, Edelstein SL, Bennett PH, Dabelea D, Hoskin M, Kahn SE, Kalyani RR, Kim C, Pi-Sunyer FX, Raghavan S, Shah VO, Temprosa M, Venditti EM, Nathan DM. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025 Jun; 13(6):469-481.
-
Low Wang CC, Estacio R, Coronel-Mockler S, Flattery N, Hanson PD, Adams RN, McKenzie AL, Harrison D, Bonaca MP. Virta Intervention in CommuniTies in ColORado (VICTOR) Pilot Study to Improve Diabetes and Cardiovascular Risk in Rural Communities - Primary Results. Endocr Pract. 2025 Jun; 31(6):790-797.
-
Berget C, Annan SF, Biester T, Choudhary P, Forlenza GP, Peters AL, Renard E, Deiss D. Practical considerations for using the Omnipod? 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025 Jun; 27(6):2909-2919.
-
Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, Bergenstal RM, Brown N, Carlson AL, DeFronzo RA, Gramzinski MR, Harindhanavudhi T, Kozedub A, Sivitz WI, Steffes MW, Balasubramanyam A, Rasouli N. Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Witham MD, McDonald C, Wilson N, Rennie KJ, Bardgett M, Bradley P, Clegg AP, Connolly S, Hancock H, Hiu S, Nicholson K, Robertson L, Simms L, Steel AJ, Steves CJ, Storey B, Wason J, von Zglinicki T, Sayer AA. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England?(MET-PREVENT): a double-blind, randomised, placebo-controlled trial. Lancet Healthy Longev. 2025 Mar; 6(3):100695.
-
Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 Jun; 19(3):341-343.
-
Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 Jun; 27(6):430-438.
-
King J, Buschur E, Garcetti R, Pyle L, Sakamoto C, Snell-Bergeon J, Nease E, Bartholomew A, Dungan K, Polsky S. Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy. J Diabetes Complications. 2025 Apr; 39(4):109000.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|